Compare IZEA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | CUE |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.5M | 27.1M |
| IPO Year | 2010 | 2017 |
| Metric | IZEA | CUE |
|---|---|---|
| Price | $3.67 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 55.8K | ★ 350.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $20,099,695.00 | $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.91 | $25.00 |
| P/E Ratio | $53.00 | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $1.68 | $0.23 |
| 52 Week High | $5.86 | $1.05 |
| Indicator | IZEA | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 45.96 |
| Support Level | $3.48 | $0.27 |
| Resistance Level | $4.28 | $0.36 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 41.67 | 40.42 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.